Pages that link to "Q26842113"
Jump to navigation
Jump to search
The following pages link to Therapeutic advances in medical oncology (Q26842113):
Displaying 50 items.
- Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies (Q24568071) (← links)
- An overview of the c-MET signaling pathway (Q24633986) (← links)
- From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases (Q26740064) (← links)
- Current targeted therapies in the treatment of advanced colorectal cancer: a review (Q26740067) (← links)
- CYP17 inhibitors in prostate cancer: latest evidence and clinical potential (Q26740070) (← links)
- Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications (Q26740072) (← links)
- Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy (Q26745418) (← links)
- Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients? (Q26745420) (← links)
- Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes (Q26745422) (← links)
- Nintedanib in NSCLC: evidence to date and place in therapy (Q26745424) (← links)
- Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer (Q26745427) (← links)
- Immunotherapy for head and neck cancer: latest developments and clinical potential (Q26745428) (← links)
- Targeting dormant micrometastases: rationale, evidence to date and clinical implications (Q26765205) (← links)
- Novel targets in the treatment of advanced gastric cancer: a perspective review (Q26765208) (← links)
- Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data (Q26769835) (← links)
- Pharmacologic resistance in colorectal cancer: a review (Q26769850) (← links)
- Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy (Q26769870) (← links)
- ALK inhibitors in non-small cell lung cancer: the latest evidence and developments (Q26769879) (← links)
- Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential (Q26769884) (← links)
- Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review (Q26775522) (← links)
- Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications (Q26775546) (← links)
- MEK and PI3K inhibition in solid tumors: rationale and evidence to date (Q26775573) (← links)
- Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies (Q26777679) (← links)
- Human epidermal growth factor receptor 2 positive (HER2 ) metastatic breast cancer: how the latest results are improving therapeutic options (Q26777681) (← links)
- Optimal management of hormone receptor positive metastatic breast cancer in 2016 (Q26777683) (← links)
- Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance (Q26795554) (← links)
- Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy (Q26795555) (← links)
- Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application (Q26795556) (← links)
- Precision medicine in colorectal cancer: the molecular profile alters treatment strategies (Q26795558) (← links)
- Taxanes: vesicants, irritants, or just irritating? (Q26851427) (← links)
- Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer (Q26862841) (← links)
- Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications (Q27001729) (← links)
- Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence (Q27010314) (← links)
- Current and future options in the management and treatment of uterine sarcoma (Q27013559) (← links)
- Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series (Q27015875) (← links)
- Treatment options in recurrent ovarian cancer: latest evidence and clinical potential (Q27692699) (← links)
- Long-term survival in a patient with glioblastoma on antipsychotic therapy for schizophrenia: a case report and literature review (Q28069940) (← links)
- Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness (Q28071303) (← links)
- Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies (Q28072897) (← links)
- Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness (Q28072902) (← links)
- Targeting intratumoral androgens: statins and beyond (Q28073619) (← links)
- Checkpoint inhibitors in lung cancer: latest developments and clinical potential (Q28076467) (← links)
- Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy (Q28077050) (← links)
- Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond (Q28077815) (← links)
- Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis (Q28078513) (← links)
- Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization? (Q28078948) (← links)
- Concepts and targets in triple-negative breast cancer: recent results and clinical implications (Q28078992) (← links)
- Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential (Q28084942) (← links)
- Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review (Q28088619) (← links)
- Nivolumab in melanoma: latest evidence and clinical potential (Q28258598) (← links)